Recently, [99mTc]Tc-ZHER2:41071 was assessed in a Phase I clinical study (ClinicalTrials.gov Identifier: NCT05203497) and demonstrated the capacity to discriminate between breast cancer tumors with high and low HER2 expression levels (Tolmachev, unpublished data). The gene discussed is ERBB2; the disease is breast carcinoma.